Strensiq
What Strensiq is used for
Strensiq is indicated for long-term enzyme replacement therapy in patients with paediatric-onset hypophosphatasia to treat the bone manifestations of the disease.
Approved use, as published by the European Medicines Agency.
What the labels mean
- Orphan medicine: for a rare disease (affecting no more than 5 in 10,000 people in the EU).
- Approved under exceptional circumstances: full data cannot be collected, usually because the disease is very rare.
Key facts
- Brand
- Strensiq
- Active substance
- asfotase alfa
- Disease area
- Hypophosphatasia
- Medicine group
- Other alimentary tract and metabolism products
- ATC code
- A16AB
- Marketing authorisation holder
- Alexion Europe SAS
- Authorised in the EU since
- 2015
Official information
In the USA
Same active substance: Strensiq
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Strensiq used for?
Strensiq is indicated for long-term enzyme replacement therapy in patients with paediatric-onset hypophosphatasia to treat the bone manifestations of the disease.
What is the active substance in Strensiq?
Strensiq contains asfotase alfa.
Who makes Strensiq?
The EU marketing authorisation holder is Alexion Europe SAS.
Is Strensiq an orphan medicine?
Yes. Strensiq is designated an orphan medicine in the EU, for a rare disease (Hypophosphatasia).
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU